Precision for Medicine, a global leader in biomarker-driven clinical research and development, recently acquired Algorics, a top clinical technologies and biometrics service provider in the biopharma industry. This acquisition brings two innovative clinical technologies to Precision for Medicine’s portfolio, enhancing their capabilities in clinical data management, biostatistics, and programming on a global scale.
The addition of Algorics strengthens Precision for Medicine’s presence in the Asia-Pacific region and allows for more efficient and consistent data conversion to meet industry standards. One of the technologies, MetaVate, facilitates metadata transformation to streamline submission readiness and bolster statistical programming services. The second technology, Clarity, offers clinical intelligence, risk-based monitoring, and study performance management to enhance trial outcomes and simplify oversight.
Nithiya Ananthakrishnan, the CEO of Algorics, expressed excitement about joining Precision for Medicine and leveraging data and technology to optimize clinical development. The integration of Algorics’ technologies and staff into Precision for Medicine will create scale, technological advantages, and greater opportunities to serve clients globally with comprehensive solutions spanning clinical research.
Precision for Medicine is a biomarker-driven clinical research and development services organization focused on targeting patient treatments more precisely and effectively. With expertise in clinical trial design, data intelligence, laboratory services, and advanced manufacturing, Precision for Medicine drives faster clinical development and approval processes. As part of Precision Medicine Group, the company has a global presence with 3,500 employees in 40 locations across North America, Europe, and Asia-Pacific.
Algorics, on the other hand, specializes in data sciences services for the life sciences industry, offering data management, biostatistics, statistical programming, and data standardization solutions. The company serves a global portfolio of biopharmaceutical and CRO clients with technology-backed data services to increase productivity and accelerate development.
For media inquiries or more information about Precision for Medicine and Algorics, please visit their respective websites. This strategic acquisition marks a significant step for Precision for Medicine in enhancing its clinical research capabilities and expanding its reach in the biopharma industry.
Source link
